Cartesian Therapeutics (NASDAQ:RNAC) Stock Rating Lowered by Zacks Research

Posted by George Bondi on Jul 2nd, 2026

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

RNAC has been the subject of a number of other research reports. Wedbush reissued an “outperform” rating and issued a $38.00 price objective on shares of Cartesian Therapeutics in a research note on Wednesday, June 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $40.00 target price on shares of Cartesian Therapeutics in a research report on Tuesday, June 9th. Cantor Fitzgerald raised Cartesian Therapeutics from a “neutral” rating to an “overweight” rating and set a $16.00 price target for the company in a research report on Monday, March 9th. HC Wainwright decreased their price objective on Cartesian Therapeutics from $30.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Finally, BTIG Research reiterated a “buy” rating and issued a $44.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday, June 9th. Five research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Cartesian Therapeutics has a consensus rating of “Hold” and an average price target of $32.60.

View Our Latest Research Report on Cartesian Therapeutics

Cartesian Therapeutics Price Performance

Shares of Cartesian Therapeutics stock opened at $10.18 on Tuesday. The stock has a market cap of $299.09 million, a price-to-earnings ratio of -1.73 and a beta of 0.59. The firm’s 50-day moving average is $7.81 and its two-hundred day moving average is $7.30. Cartesian Therapeutics has a 1 year low of $5.60 and a 1 year high of $15.57.

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.62). The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.22 million. On average, equities analysts expect that Cartesian Therapeutics will post -4.09 earnings per share for the current year.

Hedge Funds Weigh In On Cartesian Therapeutics

A number of large investors have recently made changes to their positions in RNAC. R Squared Ltd acquired a new stake in shares of Cartesian Therapeutics in the 4th quarter worth $74,000. Sei Investments Co. purchased a new stake in Cartesian Therapeutics in the first quarter valued at about $78,000. Wells Fargo & Company MN raised its stake in Cartesian Therapeutics by 49.2% in the fourth quarter. Wells Fargo & Company MN now owns 11,762 shares of the company’s stock valued at $85,000 after buying an additional 3,878 shares during the last quarter. Miller Financial Services LLC boosted its holdings in Cartesian Therapeutics by 17.2% in the fourth quarter. Miller Financial Services LLC now owns 13,643 shares of the company’s stock worth $98,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in Cartesian Therapeutics in the fourth quarter worth about $112,000. 86.95% of the stock is owned by institutional investors and hedge funds.

About Cartesian Therapeutics

(Get Free Report)

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.